Farmas USA

DEntro de APPY a 2,40 aprovechando el pull-back a la MM50.

Completo resumen de $heff:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82416656

APPY

Hola Naftalina....si que se sigue a AMRN, pero al menos yo desde las sombras...estoy con un -40% y sin cash para promediar.....a ver si tenemos suerte mañana!!!

Its like a lottery!!!

AMRN

Yo ando toda la semana de viaje y no puedo postear, pero claro que seguimos AMRN y sigo con ella. Si alguno puede mostrar un konkorde se lo agradeceria. Ver quien entra y quien sale seria de utilidad.
Lo de AMRN ahora es "como" lo de ARNA cuando se fue de los 13$ a los 7$. Y AMRN va a empezar a vender pastillitas YA, ARNA aun estamos esperando. Paciencia compañeros. Que AMRN tenga un market cap de 1.3B es ridiculo, pero asi es esto. Necesitamos un NCE=yes para que tengamos BO. El delay no vale y un "no" tampoco porque el CEO y todo el comite de direccion no van a aceptar el precio de venta que conllevaria teniendo en cuenta que para el Q3-Q4 de 2013 estara todo lo del ANCHOR en pleno auge y eso es mucho mas gordo que lo que tenemos ahora entre manos.
En fin, esperar queda, no hay otra. Y mientras lo hacemos, que los reportes de ventas hablen por si solos.

Yo me salí ayer con una perdida de un 5% más o menos, sobre la última caída gorda. No me fío mucho, esperaba un rebote rápido y tampoco he visto sangre azul entrando. Mucha suerte a los que estáis dentro.

Saludos.

AMRN

APPY. Ayer se publicaron 8 compras de insiders a 2,10$.
Tiene buena pinta.
http://ih.advfn.com/p.php?pid=squote&symbol=APPY

Entrevista con el CEO:

QUESTION- Describe the company product(s) and value proposition

Steve Lundy: Aspen Bio is developing a blood test (AppyScore™) to assist emergency room physicians rule out abdominal pain for patients who present with abdominal pain. The test will be run on a small instrument and the test results will come back to the physician in less than an hour. Currently, there is no approved blood test in this space and physicians order CT scans and other imaging procedure which are both expensive and dangerous. It is well documented that abdominal CT scans lead to cancers later in life. A blood test with high negative predictive value (NPV) could eliminate many of these unnecessary CT scans (most patients who present with abdominal pain do not have appendicitis) and save time and money.

QUESTION- What is the size of the market for the product?

Steve Lundy: Over 9 million patients present annually to ERs in the US with abdominal pain. This is the single largest reason for ER visits. We believe that approximately 6 million of these patients would be candidates for our blood test. We have not finalized pricing for the test but we believe pricing will be in the $100 range. When we take into account the international opportunity, we believe the global market size to be in the $1 billion range.

QUESTION- What is the status of the product?

Answer- In 2011 we completed a 503 patient study across 11 hospitals in the United States. The performance was excellent; the test performed at a negative predictive value (NPV) of 97%. Clinicians have indicated that they would be highly motivated to order a test that performs at this level. Our next step in the US is to complete an FDA pivotal trial which is scheduled to start in Q3 of 2012 and finish in Q1 of 2013. The FDA trial will be very similar in design to the study we completed in 2011. We plan to launch in Europe in Q4 of 2012; there is no requirement for an FDA pivotal trial for European launch.

Steve Lundy- Describe the science and intellectual property behind the product

QUESTION: Our blood test combines the results of three protein biomarkers into a “score” which is calculated using a proprietary software algorithm. The biomarkers include MRP 14/18 (proprietary to Aspen Bio), C-Reactive Protein and White Blood Count (WBC). By combining biomarkers, we help ensure the negative predictive value of the test is high no matter when the patient presents to the ER with symptoms. We have been issued patents for the use of the MRP 14/18 biomarker in appendicitis and have filed patents for the use of the multi-marker panel and our software algorithm. We feel that our IP protection is very robust.

QUESTION- What is the cash position and runway for the company?

Steve Lundy- The company just completed a $12 million capital raise. We believe this will provide the company with sufficient capital to obtain FDA approval for AppyScore and obtain significant clinical traction in the marketplace.

QUESTION- Describe the relevant experience of the executive management team

Steve Lundy- Our senior management team has significant experience launching new in-vitro diagnostic tests into the clinical marketplace. I have over 25 years of experience in the diagnostics industry and have had fairly significant success. I recently ran commercial operations for GeneOhm Sciences which launched an infectious disease diagnostic test and sold the company to Becton Dickinson (BD) 18 months later for $230 million. Chief Commercial Officer Don Hurd has 30 years industry experience and has also led high growth commercial efforts. In addition, the company employs very experienced managers in the critical areas of manufacturing and regulatory affairs.
http://www.biomedreports.com/20120727100751/aspenbio-pharmas-ceo-chats-with-us-about-appyscore.html

NPSP a punto de caramelo.
Cita con la FDA el 29 de este mes.

NPSP

Hola chicos, buenos días.

Esto es Offtopic total, pero vengo cabreado a más no poder.

Bankinter, mi banco de toda la vida.... hasta ahora!!

1.- Si llamas por teléfono y pides hablar con un operador, ahora te cobran 1 euro COMISION + llamada
2.- Si sacas menos de 90 euros en un cajero: COMISION
3.- La COMISION de mantenimiento de la cuenta sin nómina, a partir del mes que viene pasa de 49 ee a 150 ee
4.- Previsión de cobrar mantenimiento también por las cuentas de valores
5.- Si llega un recibo y no hay fondos, ya no avisan para que hagas la correspondiente transferencia. Ahora recibo devuelto y punto.
6.- Tarjeta Credito: COMISIÓN!! (no era gratis si tenias ciertos fondos??)

y luego todos los días con correitos que si son el mejor banco, los mejores depósitos, los que mejor están en ranking quenadiesabequerankinesese.com

Señores, eso en mi pueblo es una cosa muy fea: robar
Consejo de mi padre para ellos: Que no muerdan la mano que les da de comer.

Este era el único banco de calle que defendía. A partir de ahora, se han ganado mis malas recomendaciones en todo el mundo.

Fin offTopic.